On-Demand Webinars

The Importance of Proper CDMO Selection for Rare Disease Drug Programs

biotech
CDMO
drug product development
fill finish
GMP compliance
pharmaceutical manufacturing
rare disease
regulatory strategy
small batch manufacturing
sterile manufacturing

Selecting the Right CDMO Can Make or Break Your Rare Disease Program

Originally aired: July 17, 2025
Speaker: Chris Olson, Sr. Director of Drug Product Sales, Alcami

Choosing the right CDMO isn’t just a decision—it’s a strategic differentiator, especially for rare disease programs where time, scale, and regulatory complexity are critical.

In this 45-minute on-demand webinar, Alcami’s Chris Olson shares what pharma and biotech teams must consider when selecting a CDMO partner to support sterile drug product manufacturing for rare diseases. From Annex 1 readiness to flexible batch sizes, this session breaks down how to align technical capabilities with patient impact.

Key Takeaways

✔️ How Annex 1–ready sterile fill-finish systems support regulatory success
✔️ Why low line loss and high batch yield are vital for rare disease therapies
✔️ What to expect from a full-service CDMO—from development to commercial supply
✔️ How to identify a partner equipped for small-scale, fast-track programs

Who Should Watch

This webinar is ideal for:
• Biotech and pharma professionals working on rare disease drug development
• Regulatory and technical decision-makers
• Clinical supply and operations teams evaluating CDMO partners

About the Speaker

Chris Olson, Sr. Director, Drug Product Sales, Alcami
Chris brings over 20 years of experience in sterile manufacturing and CDMO strategy. At Alcami, he leads drug product partnerships and helps innovators navigate complex manufacturing needs with agility, precision, and compliance.

"*" indicates required fields

Lookup*
You can unsubscribe from these communications at any time. For more information on how to unsubscribe, our privacy practices, and how we are committed to protecting and respecting your privacy, please review our Privacy Policy.*
Related Topics
Discovery to Commercialization: The Right Partnerships are Key to Streamlined Drug Development
Quality by Design: The Importance of Reference Standards in Drug Development
Unlocking the Future: Navigating the Next Phase of Biologics through the CDMO Lens
Contact Alcami
What do you want to know?
Some query